Therapeutic Solutions International Subsidiary Campbell Neurosciences Identifies T Regulatory Cells as a Mechanism of Stem Cell Suppression of Schizophrenia Pathology in an Animal Model

Rhea-AI Summary

Therapeutic Solutions International (OTC Markets: TSOI) has released significant research indicating that stem cell therapy may alleviate schizophrenia symptoms through the induction of T regulatory cells. Their findings show enhanced levels of anti-inflammatory cytokines and FoxP3-expressing cells in treated mice. The team aims to file an investigational new drug (IND) application with the FDA for clinical trials. CEO Kalina O'Connor emphasizes the urgency of addressing this condition, while CMO Dr. James Veltmeyer advocates for a new approach to treatment based on immunology.

Positive

• Research indicates potential for stem cell therapy to significantly improve schizophrenia symptoms.
• Findings suggest immunological involvement in schizophrenia, opening new treatment avenues.
• Plans to file IND application with FDA for clinical trials, indicating progress toward commercialization.

Negative

• None.

ELK CITY, Idaho, June 2, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported today a series of experiments, covered by its >1000 claim patent application filed in September 2020, which demonstrate stem cell activity against schizophrenia is associated with T regulatory cell induction.

The experiments demonstrated that mice, which responded to stem cell therapy possessed increased levels of anti-inflammatory cytokines interleukin-4 and interleukin-10, as well as augmented levels of cells expressing FoxP3, a marker characteristic of T regulatory cells. Depletion of T regulatory cells was capable of reducing some of the symptoms of schizophrenia in mice.

"Schizophrenia is one of the biggest predisposing factors to suicide, we at Campbell Neurosciences vow to work diligently and effectively to make schizophrenia a thing of the past," said Kalina O'Connor, President and CEO of Campbell Neuroscience. "I am thankful to our scientific team and collaborators who are working at breakneck speed to obtain as much data as possible so that we may file an investigational new drug (IND) application with the FDA to initiate clinical trials."

"This data strongly supports immunological involvement in schizophrenia, a condition that despite affecting approximately 1% of the population, is still treated in a very empirical manner with little understanding of the molecular mechanisms of the disease, or the currently used treatments," said Dr. James Veltmeyer, Chief Medical Officer of the Company.  "We are hoping to use the immunomodulatory properties of adult stem cells to alter several neurological abnormalities that we and others have identified in schizophrenia. To our knowledge, we are the only group utilizing immunology and stem cells to approach this horrific condition."

"This is exciting data and a prime example of the great synergy between our spin-off, Campbell Neurosciences and Therapeutic Solutions," said Timothy Dixon, President and CEO of Therapeutic Solutions International and co-inventor. "By cross-pollinating our work in immunology and neurology, we are making new discoveries at an incredibly rapid pace and we plan on translating these into patents, IND's, and eventually new medicines to treat patients with terrible condition like schizophrenia and cancer." 

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/ 

ir@tsoimail.com

View original content:http://www.prnewswire.com/news-releases/therapeutic-solutions-international-subsidiary-campbell-neurosciences-identifies-t-regulatory-cells-as-a-mechanism-of-stem-cell-suppression-of-schizophrenia-pathology-in-an-animal-model-301303857.html

SOURCE Therapeutic Solutions International

FAQ

What did Therapeutic Solutions International announce on June 2, 2021?

Therapeutic Solutions International reported research findings indicating the potential of stem cell therapy to alleviate schizophrenia symptoms through T regulatory cell induction.

What are T regulatory cells and their role in the new research from TSOI?

T regulatory cells are immune cells that, according to TSOI's research, may play a key role in the effectiveness of stem cell therapy for treating schizophrenia.

What is the ticker symbol for Therapeutic Solutions International?

The ticker symbol for Therapeutic Solutions International is TSOI.

When did Therapeutic Solutions International file their patent application?

The patent application was filed in September 2020.

What is the next step for TSOI regarding their stem cell research findings?

TSOI plans to file an investigational new drug (IND) application with the FDA to initiate clinical trials.